ERBB2 and breast carcinoma: The potential of TKIs to cross the blood–brain barrier opens the door to the treatment of HER2-positive breast cancer with CNS metastasis, and the increasing implication of TKIs in the treatment and combination treatment of metastatic breast cancer make for a promising outlook for TKI research in the future.